Mankind Pharma Secures Strong Credit Ratings for ₹1000 Cr Bank Facilities

Mankind Pharma's total bank facilities, amounting to ₹1,000 crore, have been assigned robust credit ratings by CARE Ratings.
This includes a 'CARE AA+; Stable' for long-term facilities and a 'CARE A1+' for short-term facilities.

What just happened (today’s filing)

Mankind Pharma announced on April 22, 2026, that CARE Ratings has assigned credit ratings for its bank facilities.

The long-term bank facilities have received a 'CARE AA+; Stable' rating.

Its short-term bank facilities were assigned a 'CARE A1+' rating.

These ratings cover a significant ₹1,000.00 crore in total bank facilities.

Why this matters

These strong credit ratings from CARE signify a high degree of safety regarding Mankind Pharma's ability to service its financial obligations.

It enhances investor confidence and can lead to more favourable borrowing terms and costs for the company.

A 'CARE AA+' rating indicates very low credit risk for long-term debt, while 'A1+' signals the lowest credit risk for short-term obligations.

The backstory (grounded)

Mankind Pharma, a leading Indian pharmaceutical player, recently underwent significant financial maneuvers, including the ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) in 2024.

Interestingly, CARE Ratings had previously withdrawn its 'CARE AA+; Stable/CARE A1+' ratings on Mankind Pharma's debt instruments in March 2025, following clarity on the funding for the BSV acquisition.

This new assignment of ratings by CARE suggests renewed confidence from the agency after the acquisition's financial impact has been assessed and integrated.

The company also faces ongoing monitoring by ICRA, which noted net debt at ₹4,300 crore or 1.3 times OPBDITA as of December 31, 2025.

What changes now

Shareholders can view this as a positive signal of the company's financial stability and its capacity to manage its debt obligations effectively.

The strong ratings may facilitate easier access to credit and potentially lower interest expenses on future borrowings.

It reinforces the market's perception of Mankind Pharma's robust financial profile post-acquisition integration.

Risks to watch

The company has been subject to an Income Tax Department search, with appeals pending against the raised demand.

Regulatory constraints on drug pricing in India and intense competition within the domestic market remain persistent industry risks.

Fluctuations in raw material prices can also impact operating margins.

Peer comparison

Other major Indian pharmaceutical companies also command strong credit ratings. For instance, Jubilant Pharmova Limited holds 'IND AA+'/Stable ratings for its bank facilities from India Ratings. Similarly, Alivus Life Sciences (formerly Glenmark Life Sciences) has 'IND AA' ratings.

These peer ratings indicate that strong credit profiles are achievable and maintained within the sector for well-performing entities.

Context metrics (time-bound)

• Revenue from operations stood at ₹12,207 crore in FY25, marking a 19% year-on-year increase.
• EBITDA margins for FY25 were reported at 25.9%, an improvement of 130 basis points year-on-year.
• Net profit for FY25 was ₹2,007 crore, up 3.4% from the previous year.

What to track next

Investors will monitor the actual utilization of these ₹1,000 crore facilities and their impact on borrowing costs.

The successful integration of Bharat Serums and Vaccines (BSV) and its contribution to financial metrics will be crucial.

Continued adherence to strong financial discipline and management of debt levels post-acquisition will be key for sustained creditworthiness.

Tracking any further actions or statements from credit rating agencies regarding Mankind Pharma's overall credit profile.